【摘要】 目的 针对新型口服抗凝药用于中国人群非瓣膜性心房颤动治疗的疗效和安全性作一荟萃分析。方法 计算机检索英文及中文数据库，检索时间截止2022年6月。纳入有关中国人群新型口服抗凝药治疗非瓣膜性心房颤动的临床研究，根据科考兰5.0.2质量评价标准评价纳入研究质量。采用RevMan 5.0软件处理数据。结果 最终纳入19个临床研究（共包括2729例患者，新型口服抗凝药组1355例，华法林组1374例）。相对于华法林组，中国人群新型口服抗凝药组卒中发生率（OR=0.56,95%CI 0.39～0.79）降低，血栓栓塞事件（非神经系统）发生率（OR=0.64,95%CI 0.43～0.94）降低，非严重出血事件发生率（OR=0.47,95%CI0.33～0.66）降低，严重出血事件发生率（OR=0.43,95%CI 0.23～0.80），凝血酶原时间、活化部分凝血活酶时间与华法林组无统计学差异（MD=1.03,95%CI-2.20～4.25;MD=-1.57,95%CI-12.28～9.15），凝血酶时间高于华法林组（MD=4.51,95%CI 4.06～4.95），纤维蛋白原数值低于华法林组（MD=-0.37,95%CI-0.50～-0.24）。结论相对于华法林组，中国人群新型口服抗凝药组卒中发生率、血栓栓塞事件（非神经系统）发生率、非严重及严重出血事件发生率均降低，凝血酶原时间、活化部分凝血活酶时间与华法林组无统计学差异，凝血酶时间高于华法林组，纤维蛋白原数值低于华法林组。更多还原

【Abstract】 Objective To systematically evaluate the efficacy and safety of new oral anticoagulants(NOACS) in the treatment of non-valvular atrial fibrillation in Chinese population.Methods The database from the establishment of the database to June 2022 was searched.The clinical studies on the treatment of non-valvular atrial fibrillation with new oral anticoagulants in Chinese population were included.The quality of the included studies was evaluated according to the Cochrane Handbook 5.0.2 quality evaluation standard.RevMan 5.0software was used to quantitatively merge the data.Results Nineteen clinical studies were finally included(including 2729 patients,1355 patients in the new oral anticoagulant group,and 1374 patients in the warfarin group) in Chinese population.The results suggested that compared with the warfarin group,the incidence of stroke(OR=0.56,95 % CI 0.39-0.79),the incidence of thromboembolic events(non-neural system)(0R-0.64,95 %CI0.43-0.94)],the incidence of non-serious bleeding events(OR=0.47,95%CI 0.33-0.66),and the incidence of serious bleeding events(OR=0.43,95%CI 0.23-0.80) were lower in the new oral anticoagulant group in Chinese population.Coagulation function(PT,APTT) were not statistically different(MD=1.03,95%CI-2.20～4.25,MD=-1.57,95% CI-12.28～9.15) between the two groups.TT was higher in the NOACS group(MD=4.51,95 % CI 4.06～4.95) and FIB was lower in the NOACS group(MD=-0.37,95%CI-0.50～-0.24) in Chinese population.Conclusions In Chinese population,compared with the warfarin group,the incidence of stroke,thromboembolic events(non-neural system),non-serious and severe bleeding events are lower in the NOACS group.The blood coagulation function(PT,APTT) is similar in the two groups.TT is higher in the NOACS group and FIB is lower in the NOACS group.更多还原